Wedbush Reaffirms “Outperform” Rating for Catabasis Pharmaceuticls Inc. (CATB)
Wedbush restated their outperform rating on shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) in a research report sent to investors on Thursday morning. They currently have a $17.00 price objective on the stock.
Separately, Zacks Investment Research upgraded shares of Catabasis Pharmaceuticls from a hold rating to a buy rating and set a $4.25 price target on the stock in a report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Catabasis Pharmaceuticls presently has an average rating of Buy and an average price target of $19.05.
Catabasis Pharmaceuticls (NASDAQ:CATB) opened at 4.76 on Thursday. The stock’s market capitalization is $73.21 million. Catabasis Pharmaceuticls has a one year low of $3.31 and a one year high of $10.83. The firm has a 50-day moving average of $4.77 and a 200 day moving average of $4.74.
Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. On average, equities research analysts anticipate that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. raised its stake in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned approximately 1.50% of Catabasis Pharmaceuticls worth $1,159,000 as of its most recent filing with the SEC. 57.27% of the stock is currently owned by institutional investors.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.